327 related articles for article (PubMed ID: 36356603)
1. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis.
Jamieson L; Johnson LF; Nichols BE; Delany-Moretlwe S; Hosseinipour MC; Russell C; Meyer-Rath G
Lancet HIV; 2022 Dec; 9(12):e857-e867. PubMed ID: 36356603
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.
Landovitz RJ; Hanscom BS; Clement ME; Tran HV; Kallas EG; Magnus M; Sued O; Sanchez J; Scott H; Eron JJ; Del Rio C; Fields SD; Marzinke MA; Eshleman SH; Donnell D; Spinelli MA; Kofron RM; Berman R; Piwowar-Manning EM; Richardson PA; Sullivan PA; Lucas JP; Anderson PL; Hendrix CW; Adeyeye A; Rooney JF; Rinehart AR; Cohen MS; McCauley M; Grinsztejn B;
Lancet HIV; 2023 Dec; 10(12):e767-e778. PubMed ID: 37952550
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial.
Marzinke MA; Hanscom B; Wang Z; Safren SA; Psaros C; Donnell D; Richardson PA; Sullivan P; Eshleman SH; Jennings A; Feliciano KG; Jalil E; Coutinho C; Cardozo N; Maia B; Khan T; Singh Y; Middelkoop K; Franks J; Valencia J; Sanchez N; Lucas J; Rooney JF; Rinehart AR; Ford S; Adeyeye A; Cohen MS; McCauley M; Landovitz RJ; Grinsztejn B;
Lancet HIV; 2023 Nov; 10(11):e703-e712. PubMed ID: 37783219
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.
Neilan AM; Landovitz RJ; Le MH; Grinsztejn B; Freedberg KA; McCauley M; Wattananimitgul N; Cohen MS; Ciaranello AL; Clement ME; Reddy KP; Hyle EP; Paltiel AD; Walensky RP
Ann Intern Med; 2022 Apr; 175(4):479-489. PubMed ID: 35099992
[TBL] [Abstract][Full Text] [Related]
5. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Mayer KH; Molina JM; Thompson MA; Anderson PL; Mounzer KC; De Wet JJ; DeJesus E; Jessen H; Grant RM; Ruane PJ; Wong P; Ebrahimi R; Zhong L; Mathias A; Callebaut C; Collins SE; Das M; McCallister S; Brainard DM; Brinson C; Clarke A; Coll P; Post FA; Hare CB
Lancet; 2020 Jul; 396(10246):239-254. PubMed ID: 32711800
[TBL] [Abstract][Full Text] [Related]
6. Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis.
Blair HA
Drugs; 2022 Sep; 82(14):1489-1498. PubMed ID: 36255686
[TBL] [Abstract][Full Text] [Related]
7. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
Baeten JM; Donnell D; Mugo NR; Ndase P; Thomas KK; Campbell JD; Wangisi J; Tappero JW; Bukusi EA; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kidoguchi L; Coombs RW; Hendrix C; Marzinke MA; Frenkel L; Haberer JE; Bangsberg D; Celum C;
Lancet Infect Dis; 2014 Nov; 14(11):1055-1064. PubMed ID: 25300863
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Ogbuagu O; Ruane PJ; Podzamczer D; Salazar LC; Henry K; Asmuth DM; Wohl D; Gilson R; Shao Y; Ebrahimi R; Cox S; Kintu A; Carter C; Das M; Baeten JM; Brainard DM; Whitlock G; Brunetta JM; Kronborg G; Spinner CD;
Lancet HIV; 2021 Jul; 8(7):e397-e407. PubMed ID: 34197772
[TBL] [Abstract][Full Text] [Related]
9. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.
Walensky RP; Horn T; McCann NC; Freedberg KA; Paltiel AD
Ann Intern Med; 2020 May; 172(9):583-590. PubMed ID: 32150602
[TBL] [Abstract][Full Text] [Related]
10. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.
Eshleman SH; Fogel JM; Piwowar-Manning E; Chau G; Cummings V; Agyei Y; Richardson P; Sullivan P; Haines CD; Bushman LR; Petropoulos C; Persaud D; Kofron R; Hendrix CW; Anderson PL; Farrior J; Mellors J; Adeyeye A; Rinehart A; St Clair M; Ford S; Rooney JF; Mathew CA; Hunidzarira P; Spooner E; Mpendo J; Nair G; Cohen MS; Hughes JP; Hosseinipour M; Hanscom B; Delany-Moretlwe S; Marzinke MA
J Infect Dis; 2022 May; 225(10):1741-1749. PubMed ID: 35301540
[TBL] [Abstract][Full Text] [Related]
12. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study.
Smith J; Bansi-Matharu L; Cambiano V; Dimitrov D; Bershteyn A; van de Vijver D; Kripke K; Revill P; Boily MC; Meyer-Rath G; Taramusi I; Lundgren JD; van Oosterhout JJ; Kuritzkes D; Schaefer R; Siedner MJ; Schapiro J; Delany-Moretlwe S; Landovitz RJ; Flexner C; Jordan M; Venter F; Radebe M; Ripin D; Jenkins S; Resar D; Amole C; Shahmanesh M; Gupta RK; Raizes E; Johnson C; Inzaule S; Shafer R; Warren M; Stansfield S; Paredes R; Phillips AN;
Lancet HIV; 2023 Apr; 10(4):e254-e265. PubMed ID: 36642087
[TBL] [Abstract][Full Text] [Related]
13. Estimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083.
Mitchell KM; Boily MC; Hanscom B; Moore M; Todd J; Paz-Bailey G; Wejnert C; Liu A; Donnell DJ; Grinsztejn B; Landovitz RJ; Dimitrov DT
Lancet Reg Health Am; 2023 Feb; 18():100416. PubMed ID: 36844011
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States.
Brogan AJ; Davis AE; Mellott CE; Fraysse J; Metzner AA; Oglesby AK
Pharmacoeconomics; 2024 Apr; 42(4):447-461. PubMed ID: 38267806
[TBL] [Abstract][Full Text] [Related]
15. HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study.
Psaros C; Goodman GR; Lee JS; Rice W; Kelley CF; Oyedele T; Coelho LE; Phanuphak N; Singh Y; Middelkoop K; Griffith S; McCauley M; Rooney J; Rinehart AR; Clark J; Go V; Sugarman J; Fields SD; Adeyeye A; Grinsztejn B; Landovitz RJ; Safren SA;
J Int AIDS Soc; 2024 May; 27(5):e26252. PubMed ID: 38783534
[TBL] [Abstract][Full Text] [Related]
16. Global HIV Incidence Analysis and Implications for Affordability Using Long-Acting Cabotegravir Versus Continuous and Event-Driven Oral Preexposure Prophylaxis.
Sharma I; Hill A
Clin Infect Dis; 2024 Feb; 78(2):386-394. PubMed ID: 37665213
[TBL] [Abstract][Full Text] [Related]
17. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.
Delany-Moretlwe S; Hughes JP; Bock P; Ouma SG; Hunidzarira P; Kalonji D; Kayange N; Makhema J; Mandima P; Mathew C; Spooner E; Mpendo J; Mukwekwerere P; Mgodi N; Ntege PN; Nair G; Nakabiito C; Nuwagaba-Biribonwoha H; Panchia R; Singh N; Siziba B; Farrior J; Rose S; Anderson PL; Eshleman SH; Marzinke MA; Hendrix CW; Beigel-Orme S; Hosek S; Tolley E; Sista N; Adeyeye A; Rooney JF; Rinehart A; Spreen WR; Smith K; Hanscom B; Cohen MS; Hosseinipour MC;
Lancet; 2022 May; 399(10337):1779-1789. PubMed ID: 35378077
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of long-acting cabotegravir versus oral tenofovir disoproxil fumarate-emtricitabine as HIV pre-exposure prophylaxis: A systematic review and meta-analysis.
Chen X; Li J; Kou L; Xie X; Wei D; Li Y
Rev Med Virol; 2023 Jul; 33(4):e2460. PubMed ID: 37198721
[TBL] [Abstract][Full Text] [Related]
19. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
[TBL] [Abstract][Full Text] [Related]
20. Population-level impact of expanding PrEP coverage by offering long-acting injectable PrEP to MSM in three high-resource settings: a model comparison analysis.
Stansfield SE; Heitner J; Mitchell KM; Doyle CM; Milwid RM; Moore M; Donnell DJ; Hanscom B; Xia Y; Maheu-Giroux M; Vijver DV; Wang H; Barnabas R; Boily MC; Dimitrov DT
J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26109. PubMed ID: 37439080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
